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Cancer cells are sneaky. They have developed ways to evade the 
immune system, and hide in plain sight from our natural defences 
against tumour progression. However, developments in cancer 
immunotherapy promise to be the most encouraging treatment 
approach for cancer since chemotherapy. What makes this even 
more exciting is that the immune system functions all over the 
body meaning immunotherapy has the potential to treat many 
different types of cancer.
What is Cancer Immunotherapy?
Following numerous promising clinical trial results, cancer 
immunotherapy was selected as the “Breakthrough of the Year” in 
2013 by Science magazine. Cancer immunotherapy is any treatment 
that modulates the immune system to attack and kill tumour cells 
through small-molecule drugs or antibodies that bind to proteins 
on the cancer or immune cells. Vaccines or T-cell therapy can also 
be used, whereby the patient’s immune cells are extracted and 
reprogrammed, then transferred back to the patients to attack 
tumours. Cancer immunotherapy combats the ability of cancerous 
cells to avoid immune system detection. One of the ways in which 
cancer cells avoid detection is via the PD-1/PD-L1 interaction.
PD-1/PD-L1: Friend or Foe
T-cells are immune cells which recognise infected or damaged 
cells, cytotoxic T-cells can then release toxins to kill these cells. 
Programmed cell death-1 (PD-1) is a protein expressed on 
the surface of cytotoxic T-cells. The binding partner of PD-1 is 
programmed cell death-ligand 1 (PD-L1). This is expressed on the 
surface of many cell types throughout the body. The T-cell is like 
an airport security guard. When you set off the scanner you are 
patted down. If you have nothing illegal or dangerous with you, 
you can continue on your trip, but if you do, you are taken away 
and possibly arrested. Similarly, the T-cell “pats down” the cells in 
your body and it does this by binding to molecules on the surface 
of the cell being “inspected”. The number and type of interactions 
between the “suspect” cell and the T-cell informs the T-cell whether 
the cell is healthy or whether it is infected or damaged. Cytotoxic 
T-cells, unlike airport security guards, take drastic action if a cell is 
found to be unhealthy and release toxins to kill the cell. Expressing 
PD-L1 on the surface of the cell sends signals to the T-cell to not 
take any action. “You have made it through airport security without 
any problems.“ 
The natural role of this PD-1/PD-L1 interaction is to promote 
tolerance and prevent autoimmune responses. Some tumours 
hijack this mechanism, over-expressing the PD-L1 protein on their 
surface. T-cells that come into contact with a tumour cell expressing 
Cancer cells can evade detection by the immune 
system by over-expressing PD-L1.
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PD-1 on its surface binds to the PD-L1 on the tumour. This sends 
a signal to the T-cell to override an immune response, aiding the 
cancer cell in escaping detection and proliferating.
Blocking the interaction of PD-1 and PD-L1, with either an 
antibody or a small-molecule drug, would prevent the inhibiting 
signal from reaching the T-cells, which may then recognise the 
cancer cell and initiate an immune response.
Antibody Therapeutics Targeting  
PD-1/PD-L1
There are currently five antibody drugs targeting the PD-1/
PD-L1 interaction that are licensed by the US Food and Drug 
Administration (FDA). Two of them bind to PD-1, and the 
remaining three to PD-L1. These drugs are licensed to treat cancers 
including melanoma, lung cancer, kidney cancer, lymphoma, and 
many more. The list keeps growing, as more and more clinical 
trials are proving successful against many different cancer types. 
The most well-known of these drugs is Pembrolizumab, also known 
by the trade name Keytruda, which was first approved in October 
2015 by the FDA. Pembrolizumab treats non-small cell lung cancer 
(NSCLC) in patients no longer responding to chemotherapy. In May 
2017, Pembrolizumab was approved as a first-line treatment along 
with chemotherapy, for NSCLC. In May 2017, the FDA approved 
Pembrolizumab as a second-line treatment for all metastatic solid 
tumour types with a specific biomarker. This was the first time 
the FDA approved a treatment based on biomarkers instead of a 
specific tumour type. The widespread use of Pembrolizumab in 
the UK did lag behind that of the US due to concerns about the 
price of the drug. However, after NICE and the pharmaceutical 
company Merck came to a confidential agreement for a reduced 
price for Pembrolizumab, NICE confirmed on the 6th of June this 
year that it is now routinely available on the NHS for treatment 
of lung cancer. Pembrolizumab is also available on the NHS for 
treatment of melanoma and bladder cancer, amongst others, for 
patients whose cancer has spread or other treatments have not 
worked. Another drug called Avelumab (Bavencio) has also been 
FDA-approved for the treatment of Merkel cell carcinoma, and 
is the first treatment of any kind to be approved for this cancer 
type, delivering a real boost to patients of this rare type of skin 
cancer. Thus, antibody therapeutics against PD-1/PD-L1 provide 
a clear example of how cancer immunotherapy is changing cancer 
treatments and improving outcomes for patients. 
Small Molecules Targeting PD-1/PD-L1
The development of small-molecule drugs that block PD-1/PD-
L1 interaction lags behind that of antibodies. Whilst antibodies 
are performing well  showing dramatic life-extending effects for 
patients, there are a number of benefits, for both pharmaceutical 
companies and for patients, on focusing development on small-
molecule therapies. Firstly the cost of manufacturing a small-
molecule drug would be much reduced for the pharmaceutical 
companies and this could help make the treatment more widely 
accessible globally. Secondly, since antibodies are proteins they 
cannot be digested and must be injected, this can be uncomfortable 
for patients as many would prefer to take a pill instead. Finally, in 
the case of solid tumours, a small-molecule could penetrate deeper 
into the tumour and improve outcomes further.
My research has focused on characterising the binding of small-
molecules shown to block the interaction in vitro to PD-L1. Using 
NMR spectroscopy I have determined the binding site of these 
small-molecules and which amino acids of PD-L1 are involved 
in binding. This research will shed light on how these non-drug-
like small-molecules can be chemically modified and improved to 
produce a drug that has in vivo affect.
Treatment of tumours with anti-PD-1 therapeutics 
dramatically reduces the size of tumours.
Comparison of the NMR spectra of PD-L1 with and without the small molecule present allows the mapping 
of the binding site of the small molecule.
